Blog
When Patients Report Side Effects: Is the Evidence Ready for Decision-Making?
New findings show why thoughtful PRO-CTCAE design, analysis, and positioning matter in oncology drug evaluation
Nov 20, 2026

New findings show why thoughtful PRO-CTCAE design, analysis, and positioning matter in oncology drug evaluation

In oncology, understanding whether a treatment works is only part of the benefit-risk equation. How patients experience treatment-related symptoms and side effects also matters.

The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, or PRO-CTCAE, was developed to systematically capture symptomatic toxicities directly from patients. Yet despite its increasing use in oncology clinical trials, PRO-CTCAE has played a relatively limited role in regulatory and health technology assessment (HTA) decision-making.

A recently published cross-agency review in JNCI: Journal of the National Cancer Institute, co-authored by IQVIA researchers, examined oncology drug submissions and assessment reports from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and HTA bodies to understand how PRO-CTCAE data are being used and what may be limiting their influence.

The findings point to an important challenge for oncology drug developers: capturing the patient perspective on treatment toxicity is not enough. The evidence must also be designed, analyzed, positioned, and communicated in ways that make it useful for decision-making.

PRO-CTCAE is recognized, but its influence remains limited

The review identified relatively infrequent incorporation of PRO-CTCAE data into regulatory and HTA decisions. PRO-CTCAE data were included in just two FDA oncology drug labels, despite agencies recognizing the potential value of these data for supplementing traditional safety information with the patient perspective.

The issue is not necessarily whether patients' own reports of symptomatic toxicity have value. Rather, the findings suggest there can be a gap between generating patient-reported safety data and generating evidence that agencies can meaningfully use.

This is particularly relevant in oncology, where treatment tolerability can be complex and conventional clinician-reported adverse-event assessments may not fully characterize how symptoms are experienced by patients.

What may be limiting the impact of PRO-CTCAE?

One of the most useful aspects of the review is its identification of recurring limitations in sponsor submissions.

These included non-transparent PRO-CTCAE item selection, inadequate positioning of PRO-CTCAE within the endpoint strategy, single-arm or open-label study designs, and missing or inconsistently reported data. According to the authors, these methodological and implementation challenges have restricted the ability of regulators and HTA bodies to use PRO-CTCAE evidence in decision-making.

These findings have implications beyond data collection itself.

Consider item selection. Selecting symptoms because they appear relevant to a treatment may be scientifically reasonable, but decision-makers also need to understand why those particular items were selected, what role they were intended to play in the evidence package, and how the resulting data should be interpreted.

The same applies to endpoint positioning. If PRO-CTCAE is included without a clearly defined role in the study or evidence-generation strategy, its potential contribution to the benefit-risk story may be difficult to establish.

In other words, the challenge is not simply Are we collecting PRO-CTCAE?

It is Are we collecting it in a way that answers a clearly defined question?

Planning patient-reported side effect evidence with decisions in mind

This points to a broader evolution in how sponsors may need to approach patient-reported safety data.

The JNCI review concludes that harmonized, cross-agency guidance on PRO-CTCAE item selection, endpoint definition, analysis, and presentation could help enable more consistent and meaningful use of these data in future oncology submissions and decision-making.

PRO-CTCAE strategy should begin well before data collection. Sponsors need to consider why the data are being generated, which symptomatic experiences are most relevant to the treatment and patient population, how well the symptomatic side effects are able to be managed, how the items and endpoints fit within the broader clinical development strategy, and how the resulting evidence could contribute to regulatory and HTA discussions.

Until that guidance evolves, thoughtful planning becomes even more important.

What should oncology sponsors do next?

For sponsors, the findings suggest that realizing the potential of PRO-CTCAE requires moving beyond a collection-first mindset.

The strongest strategies will connect the patient-reported symptomatic toxicity evidence to a clear decision context from the beginning. That means considering study design, item selection, endpoint definition, analysis, interpretation, and communication as interconnected components rather than separate activities.

Sponsors developing an oncology evidence strategy should be asking:

  • Why are we collecting PRO-CTCAE, and what decision is it intended to inform?
  • Can we clearly justify the symptoms and items selected for measurement?
  • Is PRO-CTCAE appropriately positioned within the endpoint and analysis strategy?
  • Does the trial design allow the findings to be interpreted in the intended context?
  • Does our strategy support managing symptomatic toxicities?
  • Are missing data and reporting approaches addressed rigorously and transparently?
  • Can regulators and HTA bodies readily understand what the results add to the overall benefit-risk story?

The emerging lesson is straightforward: the value of patient-reported toxicity data depends not only on capturing the patient voice, but on making that voice interpretable and actionable for the people making decisions about new treatments.

As PRO-CTCAE use continues to grow in oncology trials, the opportunity is clear. Sponsors who plan patient-reported side-effect evidence with decisions in mind will be better positioned to show regulators, HTA bodies, and ultimately patients how a treatment is likely to feel, not just how well it works. The JNCI study offers a useful roadmap for getting there.

IQVIA Patient Centered Solutions helps sponsors put that roadmap into practice. From clinical outcome assessment (COA) strategy and endpoint development to analysis, interpretation, and regulatory positioning, we work across the development lifecycle to turn the patient perspective into evidence that can meaningfully inform healthcare decisions. If you are planning to include PRO-CTCAE or other patient-reported measures in an upcoming oncology program, now is the right time to start that conversation.

About the study: Authors include Ethan Basch (University of North Carolina Lineberger Comprehensive Cancer Center); Joanne Buzaglo and Jessica Roydhouse (IQVIA); Matthew Reaney and Montserrat Casamayor (formerly IQVIA); Bellinda L. King-Kallimanis (LUNGevity Foundation); Daneen Sekoni (Cancer Support Community); and Robert Caruano, Chieh-I Chen, Ruben G. W. Quek, Vera Mastey, James Harnett, and Lei Chi (Regeneron Pharmaceuticals, Inc.).

Read the full JNCI publication: PRO-CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe

Related solutions